Search

Your search keyword '"Eandi, C. M."' showing total 15 results
Start Over Author "Eandi, C. M."
15 results on '"Eandi, C. M."'

1. Biomarkers in early response to brolucizumab on pigment epithelium detachment associated with exudative age‐related macular degeneration

Author

Rispoli, M., Eandi, C. M., Di Antonio, L., Kilian, R., Montesel, A., Savastano, Maria Cristina, Savastano M. C. (ORCID:0000-0003-1397-4333), Rispoli, M., Eandi, C. M., Di Antonio, L., Kilian, R., Montesel, A., Savastano, Maria Cristina, and Savastano M. C. (ORCID:0000-0003-1397-4333)

Abstract

Background: The purpose of this study was to describe early changes in the morphology of pigment epithelium detachments (PED) after an intravitreal injection of Brolucizumab into eyes with macular neovascularization secondary to exudative age‐related macular degeneration (e‐ AMD). Method: We included twelve eyes of 12 patients with PED secondary to e‐AMD which were not responding to prior anti‐VEGF treatments. An ophthalmic examination and an assessment of PED‐horizontal maximal diameter (PED‐HMD), PED‐maximum high (PED‐MH) and macular neo-vascularization (MNV) flow area (MNV‐FA) by the means of structural optical coherence tomogra-phy (OCT) and OCT Angiography (OCT‐A) were performed at baseline, as well as 1, 7, 14 and 30 days after the injection. Results: The mean age of the population of study was 78.4 (SD ± 4.8). The mean number of previous Ranibizumab or Aflibercept injections was 13 (SD ± 8). At the last follow-up visit, the PED‐HMD did not significantly change (p = 0.16; F(DF:1.94, 20,85) = 1.9), the PED‐MH showed a significant reduction [p = 0.01; F(DF:1.31, 14.13) = 6.84.] and the MNV‐FA did not significantly differ (p = 0.1; F(1.97, 21.67) = 2.54) from baseline. No signs of ocular inflammation were observed during follow‐up. Conclusions: A single Brolucizumab injection was able to determine the short‐term effects on PEDs’ anatomical features of eyes with an unresponsive e‐AMD.

Published
2021

2. An international collaborative evaluation of central serous chorioretinopathy: different therapeutic approaches and review of literature. The European Vitreoretinal Society central serous chorioretinopathy study

Author

Romano, M. R., Parolini, B., Allegrini, D., Mickalewska, Z., Adelman, R., Bonovas, S., Bopp, S., Citirik, M., Tekin, K., Fiser, I., Boon, C. J. F., Van, D., Donvito, G., Gungel, H., Ozdogan Erkul, S., Unsal, E., Osmanbasoglu, O., Dincer, N., Ercalik, N. Y., Yenerel, N. M., Amar, J. -P., Ennemoser, A., Besozzi, G., Sallam, A. A. B., Ellabban, A. A., Chang, W., Eandi, C. M., Demir, M., Lee, J., Pak, K., Arrevola, L., Sloka, A., Morawski, K., Kulig - Stochmal, A., Romanowska - Dixon, B., Striebe, N. -A., Feltgen, N., Hoerauf, H., Inan, U. U., Tanev, I., Dyrda, A., Schuler, A., Lucke, K., Brix, A., Pape, S., Kusserow-Napp, C., Loo, P. A., Kanra, A. Y., Ardagil Akcakaya, A., Ari Yaylali, S., Bae, S. H., Kim, H. K., Kim, S. J., Han, J. R., Nam, W. H., Odrobina, D., Lavaque, E., Bertelli, E., Coser, S., Ziemssen, F., Forlini, M., Benatti, C., Cavallini, G. M., Stefanickova, J., Berrod, J. -P., Saksonov, S., Lytvinchuk, L., Moussa, M., Stefaniotou, M., Christodoulou, E., Zayed, M. A., Oz, O., Tassinari, P., Koch, P., Declercq, C., Johnston, R., Rusnak, S., Penas, S., Ozdek, S., Ucgul, Y., Cisiecki, S., Dziegielewski, K., Klimczak, D., Michalewska, Z., Michalewski, J., Nawrocka, Z., Nawrocki, J., Ornafel, K., Pikulski, Z., Maciej, M., Acar, N., Elshafei, M. M., Hamon, F., Soyeur, R., Badat, I., Brousseau, B., Hermouet, E., Peiretti, E., Lee, J. -H., Ferreira, N., Yoon, H. -S., Alkhars, W. I., Dudani, A., Minu, R., Telang, O., Morepatil, V. G., Furtado, M. J., Y. -J., Jo, Piccolino, F. C., Finzi, A., Ophthalmology, and Amsterdam Neuroscience - Complex Trait Genetics

Subjects
Pars plana, medicine.medical_specialty, Visual acuity, medicine.medical_treatment, Vitrectomy, 03 medical and health sciences, 0302 clinical medicine, PDT, Ophthalmology, medicine, central serous chorioretinopathy, First episode, Aspirin, Univariate analysis, medicine.diagnostic_test, business.industry, General Medicine, Fluorescein angiography, eye diseases, laser, Serous fluid, medicine.anatomical_structure, 030221 ophthalmology & optometry, medicine.symptom, business, 030217 neurology & neurosurgery, medicine.drug
Abstract

Purpose: To study and compare the efficacy of different therapeutic options for the treatment of central serous chorioretinopathy (CSCR). Methods: This is a nonrandomized, international multicentre study on 1719 patients (1861 eyes) diagnosed with CSCR, from 63 centres (24 countries). Reported data included different methods of treatment and both results of diagnostic examinations [fluorescein angiography and/or optical coherent tomography (OCT)] and best-corrected visual acuity (BCVA) before and after therapy. The duration of observation had a mean of 11 months but was extended in a minority of cases up to 7 years. The aim of this study is to evaluate the efficacy of the different therapeutic options of CSCR in terms of both visual (BCVA) and anatomic (OCT) improvement. Results: One thousand seven hundred nineteen patients (1861 eyes) diagnosed with CSCR were included. Treatments performed were nonsteroidal anti-inflammatory eye drops, laser photocoagulation, micropulse diode laser photocoagulation, photodynamic therapy (PDT; Standard PDT, Reduced-dose PDT, Reduced-fluence PDT), intravitreal (IVT) antivascular endothelial growth factor injection (VEGF), observation and other treatments. The list of the OTHERS included both combinations of the main proposed treatments or a variety of other treatments such as eplerenone, spironolactone, acetazolamide, beta-blockers, anti-anxiety drugs, aspirin, folic acid, methotrexate, statins, vitis vinifera extract medication and pars plana vitrectomy. The majority of the patients were men with a prevalence of 77%. The odds ratio (OR) showed a partial or complete resolution of fluid on OCT with any treatment as compared with observation. In univariate analysis, the anatomical result (improvement in subretinal fluid using OCT at 1 month) was favoured by age 500 μm (p = 0.03). The OR for obtaining partial or complete resolution showed that anti-VEGF and eyedrops were not statistically significant; whereas PDT (8.5), thermal laser (11.3) and micropulse laser (8.9) lead to better anatomical results with less variability. In univariate analysis, the functional result at 1 month was favoured by first episode (p = 0.04), height of subretinal fluid >500 μm (p

Published
2019
Full Text
View/download PDF

12. Brimonidine is Neuroprotective in Animal Paradigm of Retinal Ganglion Cell Damage

Author

Giulia Di Benedetto, Robert Rejdak, Federica Conti, Filippo Drago, Renato Bernardini, Giuseppina Cantarella, Mario Damiano Toro, Chiara M Eandi, Giovanni Luca Romano, Claudio Bucolo, Francesca Lazzara, Conti, F., Romano, G. L., Eandi, C. M., Toro, M. D., Rejdak, R., Di Benedetto, G., Lazzara, F., Bernardini, R., Drago, F., Cantarella, G., and Bucolo, C.

Subjects
medicine.medical_specialty, genetic structures, PERG, Glaucoma, brimonidine, ischemia-reperfusion, neuroprotection, retinal ganglion cells, RM1-950, Retinal ganglion, Neuroprotection, Optic neuropathy, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Neurotrophic factors, Ophthalmology, medicine, Pharmacology (medical), Original Research, Pharmacology, business.industry, Brimonidine, Retinal, medicine.disease, eye diseases, medicine.anatomical_structure, Retinal ganglion cell, chemistry, 030221 ophthalmology & optometry, Therapeutics. Pharmacology, sense organs, business, 030217 neurology & neurosurgery, medicine.drug
Abstract

To investigate the neuroprotective effect of brimonidine after retinal ischemia damage on mouse eye. Glaucoma is an optic neuropathy characterized by retinal ganglion cells (RGCs) death, irreversible peripheral and central visual field loss, and high intraocular pressure. Ischemia reperfusion (I/R) injury model was used in C57BL/6J mice to mimic conditions of glaucomatous neurodegeneration. Mouse eyes were treated topically with brimonidine and pattern electroretinogram were used to assess the retinal ganglion cells (RGCs) function. A wide range of inflammatory markers, as well as anti-inflammatory and neurotrophic molecules, were investigated to figure out the potential protective effects of brimonidine in mouse retina. In particular, brain-derived neurotrophic factor (BDNF), IL-6, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its death receptor DR-5, TNF-α, GFAP, Iba-1, NOS, IL-1β and IL-10 were assessed in mouse retina that underwent to I/R insult with or without brimonidine treatment. Brimonidine provided remarkable RGCs protection in our paradigm. PERG amplitude values were significantly (p < 0.05) higher in brimonidine-treated eyes in comparison to I/R retinas. Retinal BDNF mRNA levels in the I/R group dropped significantly (p < 0.05) compared to the control group (normal mice); brimonidine treatment counteracted the downregulation of retinal BDNF mRNA in I/R eyes. Retinal inflammatory markers increased significantly (p < 0.05) in the I/R group and brimonidine treatment was able to revert that. The anti-inflammatory IL-10 decreased significantly (p < 0.05) after retinal I/R insult and increased significantly (p < 0.05) in the group treated with brimonidine. In conclusion, brimonidine was effective in preventing loss of function of RGCs and in regulating inflammatory biomarkers elicited by retinal I/R injury.

Published
2021

13. Effects of circadian rhythm disruption on retinal physiopathology: Considerations from a consensus of experts.

Author

Parravano M, Eandi CM, Figus M, Lupidi M, Menchini F, Nicolo M, Parisi V, Toto L, Viola F, Vujosevic S, and Querques G

Subjects
Animals, Circadian Rhythm physiology, Consensus, Humans, Mice, Retina physiology, Diabetes Mellitus, Type 2 metabolism, Melatonin metabolism, Melatonin pharmacology
Abstract

The circadian rhythms originate within the organism and synchronize with cyclic fluctuations in the external environment. It has been demonstrated that part of the human genome is under control of the circadian clock and that a synchronizer that helps to maintain daily rhythms is Melatonin, a neuro-hormone primarily synthesized by the pineal gland during the night. The chronic disruption of circadian rhythm has been linked to many conditions such as obesity, metabolic syndrome, type 2 diabetes, cancer, and neurodegenerative diseases. Studies in the mice showed that the disruption of the retinal circadian rhythm increases the decline during the aging of photoreceptors, accelerating age-related disruption of cone cell structure, function, and viability and that the melatonin receptor deletion seems to influence the health of retinal cells, speeding up their aging. In conclusion, preserving the circadian rhythms could be to add to the prevention and treatment of age-related degenerative retinal diseases, and although additional studies are needed, melatonin could be a valid support to favor this "chronoprotection action".

Published
2022
Full Text
View/download PDF

14. Transpupillary thermotherapy of juxtafoveal recurrent choroidal neovascularization.

Author

Cardillo Piccolino F, Eandi CM, Ventre L, Rigault De La Longrais RC, and Grignolo FM

Subjects
Aged, Choroidal Neovascularization etiology, Coloring Agents, Female, Fluorescein Angiography, Follow-Up Studies, Fovea Centralis, Humans, Indocyanine Green, Low-Level Light Therapy, Macular Degeneration complications, Male, Pupil, Recurrence, Visual Acuity, Choroidal Neovascularization therapy, Hyperthermia, Induced methods
Abstract

Purpose: To evaluate the effectiveness of low power transpupillary thermotherapy (TTT) in treating juxtafoveal recurrent choroidal neovascularization (CNV) after laser photocoagulation in patients with age-related macular degeneration (ARMD)., Methods: Eight eyes of eight patients with ARMD and juxtafoveal recurrent CNV were treated with low power TTT, delivered using an 810-nm diode laser with 350 mW, 2.0 mm spot, and 1-minute duration. Visual acuity (VA) ranged from 20/100 to 20/50. Treatment effect was evaluated by fluorescein angiography, indocyanine green angiography, and VA measurements (Early Treatment Diabetic Retinopathy Study) at 1-week, 2-week, and monthly follow-up visits., Results: No retinal damage was visible ophthalmoscopically during treatment. At the first follow-up visit, seven eyes had obliteration of CNV and one eye required a second TTT application. VA was unchanged in six eyes, improved in one eye, and worsened in one eye. Recurrences occurred in all eyes between 1 and 7 months after TTT and were treated with photodynamic therapy (PDT). More than two PDT treatments were performed in each eye in the year after recurrence., Conclusions: Low power TTT is as able to close juxtafoveal recurrent CNV as is high power conventional laser photocoagulation but does not prevent recurrences. Further intervention with TTT in order to treat recurrences is under investigation.

Published
2003
Full Text
View/download PDF

15. Ocular angiogenesis; a new in vivo experimental model.

Author

Grignolo FM, Emanuelli L, Eandi CM, and Brogliatti B

Subjects
Aged, Animals, Biocompatible Materials, Collagen, Diabetic Retinopathy complications, Diabetic Retinopathy metabolism, Disease Models, Animal, Drug Combinations, Endothelial Growth Factors metabolism, Extracellular Matrix, Female, Fibroblast Growth Factor 2 metabolism, Fluorescent Antibody Technique, Indirect, Glaucoma, Neovascular complications, Glaucoma, Neovascular metabolism, Humans, Laminin, Lymphokines metabolism, Male, Mice, Middle Aged, Neovascularization, Pathologic etiology, Neovascularization, Pathologic pathology, Proteoglycans, Tumor Necrosis Factor-alpha metabolism, Vascular Endothelial Growth Factor A, Vascular Endothelial Growth Factors, Aqueous Humor physiology, Neovascularization, Pathologic metabolism
Published
1997
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results